Human Interleukin-2 (IL-2) (Proleukin)
Phase 3Protein / enzyme
Human Interleukin-2 (IL-2) (Proleukin) is one of 40 small molecule programs targeting Chronic Spontaneous Urticaria. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Human Interleukin-2 (IL-2) (Proleukin)
NNova Scotia Health Authority
Phase 3
Lexiscan
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- NNova Scotia Health Authority